Enough with the nonsense hedge fund garbage. This happens every third Thursday of every month.
Please take your meds today. We don't need a repeat performance from you.
I highly doubt it. The only person that probably thinks this has much bearing on CUR's future is the STEM pumper.
I work at a trading firm. It's not a naked short. Short volume means nothing. I can sell 1000 shares short and buy it back at a lower price and my position ends up being zero and I generated 1000 shares of short volume.
"No one talks about good AMD cures, or good cervical spine science on this place. Where is the talk about brilliant cures for all that ails the world?"
These cures will happen with other companies. STEM has been around for 25 years and what have the produced other than their own PRs? Where is the validation? The peer reviewed data? It doesn't exist. They have lost 2 CIRM funding opportunities and will likely never get another. Their AMD trial will be irrelevant with OCAT's peer reviewed data. The spinal cord trial will be a distant second to CUR's. Without extremely positive data from these trials STEM is doomed. Hundreds of millions of dollars wasted.
Say hello to our buddy.
His latest was GERN. He hailed it as the second coming and then dumped it and moved on.
STEM isn't worth 25 cents to CUR. CUR has their own neural stems cells that appear to work better
Message boards are filled with people who believe in all kinds of wacky manipulation conspiracies if a stock doesn't go up as expected.
The comment has nothing to do with the stock price. He said "The presentation was a rehash of last year's ASH presentation. Nothing more. Nothing less."
You said "The presentation was a rehash of last year's ASH presentation". This is completely WRONG! Just admit it.
I made no reference to the share price.
"How anyone can call tonight's presentation "Amazing" is beyond my realm of comprehension. The presentation was a rehash of last year's ASH presentation. Nothing more. Nothing less."
-Last years ASH was 22 patients and this year it was 33 patients and the CR/PR/CL ratio stayed the same.
-Do you understand the meaning of durability ? 1 year later and the patients are still CR/PR/CL. This is significant.
-5 out of 9 MDS patients remain in study many months later. These patients usually die in 2-3 months. They are starting a phase 2 based on results.
Maine, you are a complete dope.
Agree with box. The J&J deal pretty much assures Imet goes to market. It's just a matter of how much GERN will be worth. A few billion $ or in the 10s of Billion $. This will play out as they determine whether the safety profile is limits it to sick patients or not .. and how many different cancer indications it will address.